Аксетин (Cefuroxime Axetil) is commonly used to manage various bacterial infections, with its primary therapeutic focus directed toward managing symptoms related to physical discomfort and assisting with maintaining functional stability. This medicine is applicable across several domains, including infections of the respiratory tract (e.g., acute bronchitis, community-acquired pneumonia), ear, nose, and throat (e.g., acute otitis media, sinusitis, tonsillitis), skin and soft tissues, and the uncomplicated urinary tract. It may be part of symptomatic management in specific cases such as early Lyme disease.

The medicine is applied in settings where symptoms create noticeable functional strain, such as persistent fever, severe localized pain, and productive cough or purulent discharge. By assisting with the management of these symptoms that interfere with daily functioning, the medication supports the patient during difficult episodes by easing distress.

“The therapeutic approach is focused on providing supportive relief that may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Acute Symptoms Used across conditions presenting with acute episodes to help address symptoms related to systemic imbalance and localized discomfort.

Regulatory References

1. NIH MedlinePlus overview on Cefuroxime

Аксетин (Cefuroxime Axetil) eligibility is defined by regulatory documents, focusing on patient allergies and specific physiological conditions.

Absolute Non-Eligibility

The medicine is strictly contraindicated for patients with known hypersensitivity or a severe allergic reaction to cefuroxime axetil, to any other medicine in the cephalosporin class, or to other beta-lactam antibiotics, such as penicillins.

Age-Group Eligibility

• Adults and Adolescents (13+): Use is generally established.
• Children: Approved for pediatric use starting at 3 months of age.
• Infants: Safety and efficacy have not been established in infants younger than 3 months.

Conditional and Restricted Use

Use is restricted or requires caution in several populations:

• Renal Impairment: Patients with markedly impaired renal function must receive a formal dosage adjustment to compensate for the drug’s slower excretion by the kidneys.
• Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed and the benefit outweighs potential risk. For nursing mothers, since the drug is excreted in breast milk, temporary discontinuation of nursing may be required.
• Comorbidities: Caution is required for patients with a history of colitis. The oral suspension form is restricted for patients with Phenylketonuria (PKU) because it contains phenylalanine.

Interactions with other medicines and products

The interaction profile for Аксетин (Cefuroxime Axetil) is officially documented regarding its co-administration with other medicines and substances. These documented interactions establish specific monitoring requirements and constraints on use.

Documented Interacting Categories and Products

Interference with Laboratory Tests

The presence of Аксетин can cause interference with certain glucose testing methods. A false-positive result for glucose in the urine may occur when using copper reduction tests (e.g., Benedict's or Fehling's solution). Conversely, the ferricyanide test for blood/plasma glucose may yield a false-negative result. Regulatory documents explicitly recommend the use of enzyme-based tests (e.g., glucose oxidase or hexokinase method) for accurate glucose determination during use.

Аксетин functions as a selective allosteric inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS), situated within the endoplasmic reticulum of target cells. The molecule binds to a non-active site region on FPPS, inducing a conformational change that lowers the enzyme's affinity for its natural substrate, isopentenyl pyrophosphate.

This inhibition of FPPS activity leads directly to a downregulation of the mevalonate pathway, restricting the intracellular availability of essential isoprenoids, specifically farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). These molecules are required for the post-translational modification, known as prenylation, of small GTPases.

By limiting FPP and GGPP, Аксетин effectively blocks the prenylation and subsequent membrane association of small GTPases. The resulting inactive, cytosolic accumulation of unprenylated GTPases prevents their normal signal transduction function, thereby disrupting intracellular signaling cascades. This molecular mechanism ultimately modulates cellular proliferation and migration pathways, leading to a distinct system-level physiological consequence on tissue growth dynamics.

How to Use Аксетин (Cefuroxime Axetil)

Аксетин is prescribed for oral administration in the form of film-coated tablets (250 mg and 500 mg) or as a powder for oral suspension (125 mg/5 mL and 250 mg/5 mL). Adherence to the prescribed frequency and specific intake conditions is required for proper use.

Dosing Schedule and Administration

Population-Specific Instructions

• Renal Impairment: Dose frequency must be reduced in patients with marked impairment of kidney function (e.g., creatinine clearance less than 30 mL/min). This typically involves giving the standard dose less often (e.g., every 24 hours or every 48 hours), or a supplementary dose is required after haemodialysis.
• Pediatrics (3 months and older): Dosing is calculated based on body weight (e.g., 10 mg/kg or 15 mg/kg) administered twice daily, with established maximum daily doses for children under 13 years.

Note: The tablet and oral suspension formulations are not substitutable on a milligram-per-milligram basis due to differences in absorption, and this constraint must be observed during dispensing.

Research evidence / Overview of studies for Аксетин

This section outlines the types of clinical research that have been conducted for Cefuroxime Axetil, describing what outcomes were measured and what areas remain uncertain, according to official scientific literature. It does not provide clinical guidance or recommendations for use.

Evidence for Infections of the Respiratory Tract

Research for respiratory issues is based on numerous short-term Randomized Controlled Trials (RCTs). These studies were designed to evaluate the drug's role in conditions characterized by periods of heightened symptom activity, specifically Community-Acquired Pneumonia (CAP) and acute flare-ups of Chronic Bronchitis (ABECB).

For CAP, studies often monitored patients who started treatment with the active drug given intravenously before switching to the oral form, a concept called sequential therapy. Research examined measures of clinical response and bacteriologic clearance—measures of whether the specific bacteria were observed to be absent from the respiratory system. For ABECB, studies mainly focused on showing whether the drug was comparable (non-inferiority) to established antibiotics, tracking patterns of clinical resolution over short-term courses.

Evidence for Infections of the Ear, Nose, and Throat (ENT)

Evidence for ENT infections, such as Pharyngitis/Tonsillitis and Acute Bacterial Maxillary Sinusitis, involves various RCTs. For Pharyngitis/Tonsillitis, studies monitored clinical and microbiologic clearance. However, trials focused on addressing the acute infection and did not establish evidence related to preventing very rare, long-term complications associated with the bacteria.

For Sinusitis, studies focused on outcomes related to physical discomfort. Findings were mixed in some placebo-controlled trials involving children, with outcomes sometimes showing ambiguous patterns of symptom change over the inactive treatment. This reflects the challenge in clinical settings of determining if the underlying cause is bacterial or viral.

Evidence Gaps and Areas for Future Study

While a large body of evidence has been gathered for common indications, certain aspects remain uncertain. Key limitations include that follow-up durations were limited for many conditions, meaning long-term effects are not fully established. Similarly, research findings for specific patient groups, such as older adults with multiple chronic illnesses, often remain insufficient, and comparative evidence against some newer strains of bacteria is lacking.

Key Studies & References Cefuroxime (Oral Route) Drug Information - NIH MedlinePlus

Common questions about Аксетин (FAQ)

Q: What should I do if I miss a dose of my Аксетин tablets?

A: According to official patient information, if a dose is missed, the general guidance suggests taking it as soon as it is remembered. However, if the time for the next scheduled dose is near, the official recommendation is to skip the missed dose instead. Official guidance states that taking a double dose to attempt to make up for a missed one is not advised.

Q: I'm pregnant. Is it safe to take this drug for a sinus infection?

A: Official product information states that there is limited data available on the use of this medicine during pregnancy. Official labeling indicates that its use is advised only when the expected benefit is considered greater than the possible risk to the fetus. It is known that the medicine is able to cross the placental barrier.

Q: What are the signs of an allergic reaction to this medicine?

A: Official regulatory warnings list signs of a serious allergic reaction, which include hives, rash, blistering, or swelling of the face, lips, tongue, or throat. Difficulty breathing is also cited as a serious symptom. Regulatory documents state that if these symptoms manifest, the discontinuation of the drug is required.

Q: Can this medicine be used to treat viral infections?

A: According to the official product label, this medicine is an antibacterial agent, meaning it works by targeting and eliminating bacteria. Therefore, it is only approved to treat infections that are known or strongly suspected to be caused by bacteria, and label information confirms it will not be effective against infections caused by viruses, such as the common cold or flu.

Q: Can I take Аксетин if I am allergic to Amoxicillin?

A: Official contraindication information states that this medicine should not be used in patients with a history of a severe allergic reaction (hypersensitivity) to any other type of beta-lactam antibiotic. Since amoxicillin is a penicillin, which belongs to the beta-lactam class, there is a risk of cross-sensitivity, and this is generally acknowledged in the product information.

Storage and Disposal of Axetin (Cefuroxime Axetil)

Official guidelines define specific storage requirements based on the product form.

Storage Conditions

The liquid suspension should be discarded after 10 days of preparation. All forms must be stored out of the sight and reach of children and safety caps must always be locked.

Disposal

Unused or expired Axetin must be disposed of in accordance with local requirements. The medicine should not be flushed down the toilet or thrown into household waste; patients should ask a healthcare professional for guidance on proper disposal.